GoodRx (NASDAQ:GDRX) Lowered to “Hold” Rating by Wall Street Zen

GoodRx (NASDAQ:GDRX) was downgraded by stock analysts at Wall Street Zen from a “buy” rating to a “hold” rating in a report issued on Sunday.

GDRX has been the subject of a number of other research reports. UBS Group reaffirmed a “reduce” rating on shares of GoodRx in a research report on Monday, January 5th. Barclays started coverage on GoodRx in a research note on Monday, December 8th. They issued an “underweight” rating and a $3.00 target price on the stock. Mizuho dropped their price target on shares of GoodRx from $5.00 to $4.00 and set a “neutral” rating on the stock in a research note on Thursday, November 6th. Jefferies Financial Group downgraded shares of GoodRx to a “hold” rating in a research report on Thursday. Finally, TD Cowen decreased their target price on shares of GoodRx from $7.00 to $6.00 and set a “buy” rating for the company in a report on Monday, November 10th. Five equities research analysts have rated the stock with a Buy rating, six have given a Hold rating and three have given a Sell rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $4.73.

GoodRx Trading Down 0.4%

Shares of NASDAQ GDRX opened at $2.56 on Friday. GoodRx has a 1 year low of $2.47 and a 1 year high of $5.81. The company has a debt-to-equity ratio of 0.81, a current ratio of 3.11 and a quick ratio of 3.11. The firm has a 50-day moving average of $2.75 and a 200 day moving average of $3.66. The stock has a market cap of $868.95 million, a P/E ratio of 28.44, a price-to-earnings-growth ratio of 0.97 and a beta of 1.45.

GoodRx (NASDAQ:GDRX) last announced its quarterly earnings data on Tuesday, November 4th. The company reported $0.08 earnings per share for the quarter, missing analysts’ consensus estimates of $0.09 by ($0.01). GoodRx had a return on equity of 9.73% and a net margin of 3.97%.The business had revenue of $196.03 million during the quarter, compared to analysts’ expectations of $195.17 million. During the same quarter last year, the company posted $0.08 EPS. GoodRx’s revenue for the quarter was up .4% compared to the same quarter last year. As a group, sell-side analysts expect that GoodRx will post 0.13 EPS for the current fiscal year.

Institutional Investors Weigh In On GoodRx

A number of large investors have recently added to or reduced their stakes in the stock. Quarry LP purchased a new stake in GoodRx during the 3rd quarter valued at $33,000. Boothbay Fund Management LLC bought a new stake in shares of GoodRx in the third quarter worth $43,000. Shay Capital LLC bought a new stake in shares of GoodRx in the third quarter worth $47,000. Cetera Investment Advisers purchased a new stake in GoodRx during the second quarter valued at $50,000. Finally, Walled Lake Planning & Wealth Management LLC bought a new position in GoodRx in the second quarter valued at about $55,000. Institutional investors own 63.77% of the company’s stock.

About GoodRx

GoodRx Holdings, Inc (NASDAQ: GDRX) operates a digital healthcare platform designed to help consumers compare prescription drug prices at retail pharmacies across the United States. Through its website and mobile applications, GoodRx aggregates pricing and discount information from a wide network of pharmacies, enabling users to access coupons and savings programs on both generic and brand-name medications. The platform also features price transparency tools that inform patients about cost variations and available discounts to alleviate the financial burden of prescription medications.

In addition to its core drug pricing service, GoodRx offers telehealth services under the GoodRx Care brand, providing virtual consultations for a range of non-emergency conditions and prescription needs.